GSK-3 as potential target for therapeutic intervention in cancer
dc.contributor.author | McCubrey, James A. | |
dc.contributor.author | Steelman, Linda S. | |
dc.contributor.author | Bertrand, Fred E. | |
dc.contributor.author | Davis, Nicole Marie | |
dc.contributor.author | Sokolosky, Melissa | |
dc.contributor.author | Abrams, Stephen L. | |
dc.contributor.author | Montalto, Giuseppe | |
dc.contributor.author | D'Assoro, Antonino B. | |
dc.contributor.author | Libra, Massimo | |
dc.contributor.author | Nicoletti, Ferdinando | |
dc.contributor.author | Maestro, Roberta | |
dc.contributor.author | Basecke, Jorg | |
dc.contributor.author | Rakus, Dariusz | |
dc.contributor.author | Gizak, Agnieszka | |
dc.contributor.author | Demidenko, Zoya N. | |
dc.contributor.author | Cocco, Lucio | |
dc.contributor.author | Martelli, Alberto M. | |
dc.contributor.author | Cervello, Melchiorre | |
dc.date.accessioned | 2016-06-16T17:37:35Z | |
dc.date.available | 2016-06-16T17:37:35Z | |
dc.date.issued | 2014-05 | |
dc.description.abstract | The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others. | en_US |
dc.identifier.citation | Oncotarget; 5:10 p. 2881-2911 | en_US |
dc.identifier.issn | 1949-2553 | |
dc.identifier.pmid | pmc4102778 | en_US |
dc.identifier.uri | http://hdl.handle.net/10342/5659 | |
dc.relation.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102778/ | en_US |
dc.subject | GSK-3 | en_US |
dc.subject | cancer stem cells | en_US |
dc.subject | Wnt/beta-catenin | en_US |
dc.subject | PI3K | en_US |
dc.subject | Akt | en_US |
dc.subject | mTOR | en_US |
dc.subject | Hedgehog | en_US |
dc.subject | Notch | en_US |
dc.subject | Targeted Therapy | en_US |
dc.subject | Therapy Resistance | en_US |
dc.subject | Mutations | en_US |
dc.subject | Rapamycin | en_US |
dc.title | GSK-3 as potential target for therapeutic intervention in cancer | en_US |
dc.type | Article | en_US |
ecu.journal.issue | 10 | en_US |
ecu.journal.name | Oncotarget | en_US |
ecu.journal.pages | 2881-2911 | en_US |
ecu.journal.volume | 5 | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- oncotarget-05-2881.PMC4102778.pdf
- Size:
- 4.74 MB
- Format:
- Adobe Portable Document Format